allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia...
4 KB (187 words) - 03:01, 26 September 2024
allosteric modulator of the mGlu2 receptor. It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. It...
6 KB (374 words) - 10:56, 13 September 2024
as baclofen. "Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence". Addex therapeutics. Retrieved 2024-02-03...
4 KB (297 words) - 04:10, 8 September 2024
mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and...
4 KB (213 words) - 09:10, 5 September 2024
ADX-47273 is a research pharmaceutical developed by Addex Therapeutics which acts as a positive allosteric modulator (PAM) selective for the metabotropic...
4 KB (303 words) - 09:49, 10 January 2024
has served on the Boards of Directors of many companies, including Addex Therapeutics (SIX: ADXN), CellZome (acquired by GlaxoSmithKline for $120 Million...
8 KB (796 words) - 06:01, 4 June 2023
Symbol Company SMI Family Listing Remarks ABBN ABB SMI ACHI Achiko 2020 ADXN Addex Pharmaceuticals 2007 ADEN Adecco SMI MID ADVN Adval Tech Holding AEVS Aevis...
21 KB (776 words) - 14:20, 17 October 2023